The Asia Pacific Sciatica Treatment Market should witness market growth of 4.3% CAGR during the forecast period (2022-2028).
The growing popularity of sciatica treatments in the automobile sector, rising consumer desire for more fuel-efficient engines, increasing use of electric cars, and other factors are all contributing to the potential development of the sciatica treatment market during the anticipated period. Researchers involved in creating a new intervention are a driving force behind the acceleration of market expansion. The intense desire for disease-specific innovative treatments further boosts the total market demand for this category. The development of medications used to treat sciatica-related problems is another driving force.
Also, the population has access to various indoor professions because of expanding industry. Because of the increasing burden, the working population spends much time sitting down. Long periods of sitting may cause sciatica to develop or become worse. As a result, the increasing number of people in the workforce may encourage the spread of sciatica treatments. Moreover, sacral and lumbar spinal tumors may cause leg paralysis and sciatic back discomfort. Thus, throughout the scheduled time, the increased incidence of cancer among the population may provide new chances for the sciatica treatment market.
One of the world's fastest-growing aging populations is in China. Due to rising life expectancy and falling birth rates, 28% of China's population is expected to be over 60 by 2040. The creation of age-friendly towns and communities where older people may flourish and continue to make significant contributions to society is essential due to the increasingly aging population. In addition, there is an increase in demand for sciatica therapy in the APAC area due to the region's aging population and growing osteoarthritis prevalence.
The China market dominated the Asia Pacific Sciatica Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $62,929.5 Thousands by 2028. The Japan market is estimated to grow a CAGR of 3.6% during (2022-2028). Additionally, The India market would display a CAGR of 4.9% during (2022-2028).
Based on Type, the market is segmented into Chronic, Acute and Others. Based on Distribution Channel, the market is segmented into Retail & Specialty Pharmacies, Hospital Pharmacies and Online Providers. Based on Drug Class, the market is segmented into Non-Steroidal anti-inflammatory, Steroids, Antidepressants and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Sorrento Therapeutics, Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals, Inc., Aurobindo Pharma Limited, Novartis AG, and Cadila Healthcare Ltd. (Zydus Cadila)
The growing popularity of sciatica treatments in the automobile sector, rising consumer desire for more fuel-efficient engines, increasing use of electric cars, and other factors are all contributing to the potential development of the sciatica treatment market during the anticipated period. Researchers involved in creating a new intervention are a driving force behind the acceleration of market expansion. The intense desire for disease-specific innovative treatments further boosts the total market demand for this category. The development of medications used to treat sciatica-related problems is another driving force.
Also, the population has access to various indoor professions because of expanding industry. Because of the increasing burden, the working population spends much time sitting down. Long periods of sitting may cause sciatica to develop or become worse. As a result, the increasing number of people in the workforce may encourage the spread of sciatica treatments. Moreover, sacral and lumbar spinal tumors may cause leg paralysis and sciatic back discomfort. Thus, throughout the scheduled time, the increased incidence of cancer among the population may provide new chances for the sciatica treatment market.
One of the world's fastest-growing aging populations is in China. Due to rising life expectancy and falling birth rates, 28% of China's population is expected to be over 60 by 2040. The creation of age-friendly towns and communities where older people may flourish and continue to make significant contributions to society is essential due to the increasingly aging population. In addition, there is an increase in demand for sciatica therapy in the APAC area due to the region's aging population and growing osteoarthritis prevalence.
The China market dominated the Asia Pacific Sciatica Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $62,929.5 Thousands by 2028. The Japan market is estimated to grow a CAGR of 3.6% during (2022-2028). Additionally, The India market would display a CAGR of 4.9% during (2022-2028).
Based on Type, the market is segmented into Chronic, Acute and Others. Based on Distribution Channel, the market is segmented into Retail & Specialty Pharmacies, Hospital Pharmacies and Online Providers. Based on Drug Class, the market is segmented into Non-Steroidal anti-inflammatory, Steroids, Antidepressants and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Sorrento Therapeutics, Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals, Inc., Aurobindo Pharma Limited, Novartis AG, and Cadila Healthcare Ltd. (Zydus Cadila)
Scope of the Study
By Type
- Chronic
- Acute
- Others
By Distribution Channel
- Retail & Specialty Pharmacies
- Hospital Pharmacies
- Online Providers
By Drug Class
- Non-Steroidal anti-inflammatory
- Steroids
- Antidepressants
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Johnson & Johnson
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Sorrento Therapeutics, Inc.
- Alkem Laboratories Ltd.
- Amneal Pharmaceuticals, Inc.
- Aurobindo Pharma Limited
- Novartis AG
- Cadila Healthcare Ltd. (Zydus Cadila)
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Sciatica Treatment Market, by Type
1.4.2 Asia Pacific Sciatica Treatment Market, by Distribution Channel
1.4.3 Asia Pacific Sciatica Treatment Market, by Drug Class
1.4.4 Asia Pacific Sciatica Treatment Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Asia Pacific Sciatica Treatment Market by Type
3.1 Asia Pacific Chronic Market by Country
3.2 Asia Pacific Acute Market by Country
3.3 Asia Pacific Others Market by Country
Chapter 4. Asia Pacific Sciatica Treatment Market by Distribution Channel
4.1 Asia Pacific Retail & Specialty Pharmacies Market by Country
4.2 Asia Pacific Hospital Pharmacies Market by Country
4.3 Asia Pacific Online Providers Market by Country
Chapter 5. Asia Pacific Sciatica Treatment Market by Drug Class
5.1 Asia Pacific Non-Steroidal anti-inflammatory Market by Country
5.2 Asia Pacific Steroids Market by Country
5.3 Asia Pacific Antidepressants Market by Country
5.4 Asia Pacific Others Market by Country
Chapter 6. Asia Pacific Sciatica Treatment Market by Country
6.1 China Sciatica Treatment Market
6.1.1 China Sciatica Treatment Market by Type
6.1.2 China Sciatica Treatment Market by Distribution Channel
6.1.3 China Sciatica Treatment Market by Drug Class
6.2 Japan Sciatica Treatment Market
6.2.1 Japan Sciatica Treatment Market by Type
6.2.2 Japan Sciatica Treatment Market by Distribution Channel
6.2.3 Japan Sciatica Treatment Market by Drug Class
6.3 India Sciatica Treatment Market
6.3.1 India Sciatica Treatment Market by Type
6.3.2 India Sciatica Treatment Market by Distribution Channel
6.3.3 India Sciatica Treatment Market by Drug Class
6.4 South Korea Sciatica Treatment Market
6.4.1 South Korea Sciatica Treatment Market by Type
6.4.2 South Korea Sciatica Treatment Market by Distribution Channel
6.4.3 South Korea Sciatica Treatment Market by Drug Class
6.5 Singapore Sciatica Treatment Market
6.5.1 Singapore Sciatica Treatment Market by Type
6.5.2 Singapore Sciatica Treatment Market by Distribution Channel
6.5.3 Singapore Sciatica Treatment Market by Drug Class
6.6 Malaysia Sciatica Treatment Market
6.6.1 Malaysia Sciatica Treatment Market by Type
6.6.2 Malaysia Sciatica Treatment Market by Distribution Channel
6.6.3 Malaysia Sciatica Treatment Market by Drug Class
6.7 Rest of Asia Pacific Sciatica Treatment Market
6.7.1 Rest of Asia Pacific Sciatica Treatment Market by Type
6.7.2 Rest of Asia Pacific Sciatica Treatment Market by Distribution Channel
6.7.3 Rest of Asia Pacific Sciatica Treatment Market by Drug Class
Chapter 7. Company Profiles
7.1 Abbott Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 SWOT Analysis
7.2 Johnson & Johnson
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental &Regional Analysis
7.2.4 Research & Development Expenses
7.3 Teva Pharmaceutical Industries Ltd.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.4 Sun Pharmaceutical Industries Ltd.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional & Segmental Analysis
7.4.4 Research & Development Expenses
7.5 Sorrento Therapeutics, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental Analysis
7.5.4 Research & Development Expenses
7.6 Alkem Laboratories Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.7 Amneal Pharmaceuticals, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental
7.7.4 Research & Development Expenses
7.8 Aurobindo Pharma Limited
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expense
7.9 Novartis AG
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.9.4 Research & Development Expense
7.10. Cadila Healthcare Ltd. (Zydus Cadila)
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expense
Companies Mentioned
- Abbott Laboratories
- Johnson & Johnson
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Sorrento Therapeutics, Inc.
- Alkem Laboratories Ltd.
- Amneal Pharmaceuticals, Inc.
- Aurobindo Pharma Limited
- Novartis AG
- Cadila Healthcare Ltd. (Zydus Cadila)
Methodology
LOADING...
